(MedPage Today) — Finerenone (Kerendia) significantly reduced albuminuria in adults with type 1 diabetes and chronic kidney disease (CKD), meeting the primary endpoint of the phase III FINE-ONE trial.
Over 6 months, the urinary albumin-to-creatinine…
Source link : https://www.medpagetoday.com/nephrology/type1diabetes/120166
Author :
Publish date : 2026-03-04 22:40:00
Copyright for syndicated content belongs to the linked Source.
